Compounds for the treatment of metabolic disorders

Details Compounds for the treatment of metabolic disorders Compounds for the treatment of metabolic disorders

C - Chemistry, Metallurgy

07

C

C07C 69/736 (2006.01) A61K 31/192 (2006.01) A61K 31/216 (2006.01) A61K 31/235 (2006.01) A61P 3/10 (2006.01) C07C 59/68 (2006.01) C07C 65/24 (2006.01) C07C 69/92 (2006.01)

Patent

CA 2513092

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. A compound of formula (I) (see formula I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1;t is 0 or 1; R2 is alkyl from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R1 is hyrdrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

La présente invention a trait à des agents de formule (I), utiles pour le traitement de divers troubles métaboliques, tels que le syndrome de résistance à l'insuline, le diabète, l'hyperlipémie, la stéatose hépatique, la cachexie, l'obésité, l'artériosclérose; dans la formule (I) : n est 1 ou 2 ; m est 0, 1, 2, 4 ou 5; q est 0 or 1; R?2¿ est alkyle comprenant 1 à 3 atomes de carbone ; R?3¿ est hydrogène, halo, alkyle comprenant 1 à 3 atomes de carbone, ou alcoxy comprenant 1 à 3 atomes de carbone ; A est phényle, substitué ou non substitué par 1 ou 2 groupes choisis parmi : halo, alkyle ayant 1 ou 2 atomes de carbone, perfluorométhyle, alcoxy ayant 1 ou 2 atomes de carbone, et perfluorométhoxy ; ou cycloalkyle ayant 3 à 6 atomes de carbone cycliques dans lequel le cycloalkyle est non substitué ou un ou deux atomes de carbone cycliques sont indépendamment mono-substitué(s) par méthyle ou éthyle ; ou un noyau hétéroaromatique ayant 1 ou 2 hétéroatomes cycliques choisis parmi N, S et O et le noyau hétéroaromatique est en liaison covalente avec le reste du composé de formule (I) par un atome de carbone cyclique ; et R?1¿ est hydrogène ou alkyle ayant 1 ou 2 atomes de carbone. En variante, lorsque R?1¿ est hydrogène, l'agent biologiquement actif peut être un sel pharmaceutiquement acceptable du composé de formule (I).

Affiliated with

Also associated with

Rating

Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1777354